Bedford LaboratoriesTM is a leading provider of generic sterile injectable medicines with a focus on acute-care hospitals, group purchasing organizations and oncology treatment centers. Bedford Laboratories develops and distributes a broad portfolio of high-quality, medically necessary medicines to patients in hospitals and clinics across the United States and Puerto Rico through authorized distributors and drug wholesalers. Founded in 1993, Bedford has one of the largest and most experienced generic injectable salesforces in the industry, and is one of the top three Abbreviated New Drug Application (ANDA) holders in the U.S. Bedford’s capabilities include Sales and Marketing, Business Development, New Product Development and Regulatory Affairs. For more information, visit www.bedfordlabs.com.
Since opening our doors more than 20 years ago, everyone at Bedford Laboratories has shared a singular goal of meeting the needs of our customers and their patients as a leader in generic sterile injectables. Founded in 1993, Bedford Laboratories has grown to become a leading provider of generic sterile injectable medicines with a focus on acute-care hospitals, Group Purchasing Organizations (GPOs), oncology treatment centers and drug wholesalers. While we were disappointed to learn that Ben Venue Laboratories, one of our longest-standing manufacturers, will cease production by the end of 2013, Bedford will continue to provide products manufactured by Ben Venue and will distribute these products until that inventory is depleted. We will also continue to supply products manufactured by our other third-party manufacturing partners today and going forward. That will not change. A full and up-to-date list of products currently available can be accessed on the Our Products section of this website.
Bedford’s parent company, Boehringer Ingelheim, recognizes the importance of our portfolio of products, including some currently listed on the U.S. Food and Drug Administration’s Current Drug Shortages Index. As a result, we are actively exploring strategic options for Bedford and its product portfolio to help ensure that these critical medicines continue to reach the patients who need them.
Bedford has one of the largest and most experienced generic injectable sales forces in the industry, and is one of the top three Abbreviated New Drug Application (ANDA) holders in the United States. As we look toward the future, we remain focused on strengthening our relationships with customers and continuing to serve the needs of patients.
Bedford Laboratories is committed to continuing to address drug shortage, one of our industry’s most prevalent concerns. We have been working closely with regulatory agencies and other third parties, including GPOs, to help ensure important medicines reach the people who need them most. It has been our experience, especially during times where a product is in critical need and considered to be in drug shortage, that GPOs are flexible, often working with multiple manufacturers in order to ensure supply to their members. We appreciate this partnership, and we hope that, together, we can continue to make progress against this industry wide challenge.
We commit to keeping you informed as we reach upcoming milestones. Thank you for your patronage and support.
For specific product availability, including full prescribing information, visit the Our Products section of this website.
Visit us at the American Society of Health-System Pharmacists 48th Midyear Clinical Meeting & Exhibition, booth #1731.
Orlando FL, December 9 - 11, 2013